169.60 -0.88 (-0.52%)
Before hours: 8:09AM EST
|Bid||0.00 x 1100|
|Ask||0.00 x 1200|
|Day's range||169.39 - 173.65|
|52-week range||109.16 - 173.65|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||26.81|
|Earnings date||20 Apr 2021|
|Forward dividend & yield||4.04 (2.43%)|
|Ex-dividend date||22 Feb 2021|
|1y target est||174.06|
Johnson and Johnson expects vaccine data next week.
Intuitive Surgical is down more than 7% since the start of this year. Does this present a buying opportunity or is it the harbinger of more bad news?
Johnson & Johnson (NYSE: JNJ) delivered an encouraging set of quarterly results on Tuesday, which included a promising -- albeit limited -- update on its coronavirus vaccine candidate. For the sprawling company's fourth quarter of fiscal 2020, revenue came in at just under $22.